To predict a drug ' 
Introduction
As US faces potential bioterrorism threats, there is tremendous urgency to speed up the process of understanding of biological agents and pathogens for homeland security and national defense. Commercially, pharmaceutical industry experts agree that cutting the time and costs involved in drug discovery and development is essential to ensuring continued productivity and profitability of drug companies in this industry. The average drug takes twelve years from discovery and costs $400 million to $1 billion to develop. The long process starts "target evaluation", a step to understand which genes/proteins and biological pathways (i.e., "targets") are truly associated with a disease phenotype and are therapeutically addressable; proceeds through "lead discovery", a step to identify biologically active chemical entities that could be optimized into useful drugs; and "lead optimization", a step to modify a potential drug compound to ensure it has the optimal properties, then finally goes to preclinical and clinical test. Each step has to be performed in a timeconsuming serial manner.
On the other hand, there is large amount of chemical structure/interaction, biological experiments, and medical data collected over years that is relevant to drug discovery. More recently, DNA and other microarray technologies are on their way to becoming standard tools of modern life sciences research (Duggan, et al, 1999) . Petabytes of life science data have being generated. Vast data generated from all these areas present significant opportunities and challenges to classify and predict drug characteristics using various databases is critical and significant. Such systems have the potential to breakthrough the efficiencies help drugs to "fail fast" before expensive later-phase trials (Walters, et al, 1998) , thus saving time and money, increase Return of Investment.
The Challenge of Predicting Drug Characteristics
Drug's toxicity and efficacy are important characteristics to predict in today's drug screening process. Here we show here as an example of using some Quantum Intelligence's proprietary databases 
Feature Clustering Method
We presented here an innovative method for feature clustering. In our example, we used the following algorithm to cluster the 3400 features into characteristic groups separately.
Let the original object-feature matrix be Fnxm, where n and m are the number of objects (compounds) and number of features respectively. We first select a subset of features (l) based on the frequencies of all the features that appears in the existing compounds as principal features. And then compute a feature-feature association matrix Cmxl of the original m features with the l principal features. The generation of Cmxl is similar to the large item association rules algorithm in data mining context (Agrawal, et al, 1993) . The association measure can be set to either correlation or lift association lift. Confidence, support and lift are used to prune the association matrix to the statistical significant level.
Use a clustering method (any kind is fine), for example, binary or K-means to split the features into k clusters using the correlation matrix Cmxl as the input. In other words, if two features are similar (grouped into one cluster), they are similar in terms of the association with the principal features.
Compute the mean values Pkxm for all the k clusters.
When the original features in each dimension are grouped, the average measure in each group is treated as a single feature. Therefore, the original features can then be projected into the corresponding groups.
Why this Feature Clustering Method
The new projected object-feature PFnxk is only k dimensional reduced from the original m dimensional (k<<m). Note the method used here behaves like the traditional Principal Components Analysis (PCA) (Johnson, 1998) , Factor Analysis (FA) (Johnson, 1998) and Latent Semantic Analysis (LSA) in the context of document clustering (Dumais, et al 1988) , however, it is quite different and has the following advantages: m can be very large and the complexity of the computation is linear with m, while PCA, FA and LSA are all based on singular-value decomposition (SVD) which is very restricted to a small m.
Each group of features are similar and has an explicit meaning to chemists or biomedical experts.
Features are grouped into characteristic groups that can be viewed as the selectivity towards certain combined drug characteristics.
Results
We clustered 1265 potential anti-cancer compounds based on about 3400 bio-features. Figure 1 shows a test gains chart for predicting a desired characteristic. Only about 10% of candidates have the desired characteristics in the population. The black gains chart is produced by using 100 features selected by domain experts based on their understanding of biomedical and chemical significance. The blue gains chart was generated by using all 3400 features, however, grouped into 100 groups using the feature clustering method described in this paper. The result from feature clustering gave much better gain that the one using expert feature selection.
Conclusions
Our feature clustering method makes drug characteristics prediction easier and better in the following senses:
All the input features work collectively better than a few selected features. This is very true especially for biology systems and life sciences problems Our feature clustering method makes it possible to cluster large descriptive features and make them available for automatic drug characteristic prediction and screening.
Acknoledgement
The project is partially supported by DARPA contract # DAAH01-03-C-R034 
